FDA
-
-
-
-
-
-
-
Beyond Air Schedules Third Fiscal Quarter 2026 Financial Results Conference Call and Webcast
-
-
-
-
-
-
-
Beyond Air names Dan Moorhead as chief financial officer
-
-
-
-
-
-
-
Beyond Air secures $32 million financing from Streeterville Capital
-
-
-
-
-
-
-
NeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in Adults
-
-
-
-
-
-
-
Beyond Air Awarded Therapeutic Gases Agreement with Premier, Inc.
-
-
-
-
-
-
-
NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism
-
-
-
-
-
-
-
NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

